Nektar Therapeutics (NKTR)

Market Cap	331.26M
Revenue (ttm)	87.25M
Net Income (ttm)	-133.04M
Shares Out	12.41M
EPS (ttm)	-9.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,823,502
Open	29.21
Previous Close	29.68
Day's Range	25.30 - 29.26
52-Week Range	6.48 - 37.38
Beta	0.56
Analysts	Strong Buy
Price Target	77.50 (+190.26%)
Earnings Date	Aug 7, 2025

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution pro...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 3, 1994
• Employees: 61
• Stock Exchange: NASDAQ
• Ticker Symbol: NKTR
• Website: https://www.nektar.com

Financial Performance

In 2024, Nektar Therapeutics's revenue was $98.43 million, an increase of 9.22% compared to the previous year's $90.12 million. Losses were -$118.96 million, -56.91% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for NKTR stock is "Strong Buy." The 12-month stock price forecast is $77.5, which is an increase of 190.26% from the latest price.

Price Target

$77.5

(190.26% upside)

Analyst Consensus: Strong Buy